FDA Authorized Generics List: How to Access and Use It

You might be looking for a cheaper version of a brand-name medication, or perhaps you're a researcher tracking how big pharma companies keep their market share. In either case, the FDA list of authorized generics is the primary public resource you need. However, finding it isn't as simple as searching "authorized generics" on Google, because these drugs don't appear in the standard databases most people use. They are unique products that sit in a regulatory gray area, making them easy to miss if you don't know exactly where to look.

This guide shows you exactly where to find this specific list, what data it contains, and-crucially-what it doesn't tell you. We will walk through the legal basis for its existence, how to interpret the dates provided, and why you might need to cross-reference other sources to get a complete picture of current market availability.

What Are Authorized Generic Drugs?

To understand the list, you first need to understand the product. An authorized generic is the same as the brand-name drug but does not use the brand name on the label. It may have a different color or marking, but chemically and therapeutically, it is identical to the original brand product. The key difference lies in how it is approved. Traditional generics go through an Abbreviated New Drug Application (ANDA) process. Authorized generics, however, are marketed under the brand-name drug's New Drug Application (NDA). This means they are not listed in the FDA's famous Orange Book, which tracks therapeutic equivalence for ANDA-approved generics. Instead, they are tracked separately under Section 505(t) of the Federal Food, Drug, and Cosmetic Act, a requirement established by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.

Where to Find the Official FDA List

The FDA maintains this information on a dedicated webpage within their drugs section. You can access the Listing of Authorized Generics directly from the FDA’s website. The page provides explanatory text about what authorized generics are, along with a link to the current PDF document containing the full list. As of the latest update, this document is a static PDF file weighing approximately 1.09 MB. It is not a searchable database yet, so you will likely need to download the file and use your computer's search function (Ctrl+F or Cmd+F) to find specific drug names. The list is updated quarterly as mandated by law, ensuring that new entries added via annual reports are reflected regularly.

Understanding the Data Elements

Once you have the PDF, you'll notice each entry contains specific data points. Here is what you are looking at:

• Proprietary Name: The brand name of the original drug (e.g., ARTHROTEC).
• Dosage Form and Strength: Details like "tablets" or "gel" and the specific milligram or microgram amount.
• NDA Applicant Name: The manufacturer responsible for the brand-name application (e.g., Pfizer Inc.).
• Date Authorized Generic Entered Market: This is the most critical-and often misunderstood-column.

A common pitfall is assuming the "Date Authorized Generic Entered Market" is the exact day the product hit pharmacy shelves. The FDA explicitly notes that this date reflects the period covered by the annual report in which the authorized generic was first reported. Since annual reports cover a year-long period, the actual launch date could be anywhere within that timeframe. For example, if a report covers January to December 2024 and lists a new authorized generic, the date might just say "2024," giving you no precise month or day.

Authorized Generics vs. The Orange Book

Many users get confused because they start their search in the Orange Book. If you search for a brand drug there, you might see "Single Source" or "No Generic Competition." That doesn't mean there is no cheaper alternative; it just means there is no *traditional* generic approved via ANDA. Authorized generics bypass this system entirely. They are considered therapeutically equivalent by definition because they are the same drug manufactured by the same company. This distinction is vital for researchers and pharmacists. If you are relying solely on the Orange Book to identify all potential cost-saving alternatives, you will miss every authorized generic currently on the market.

Practical Limitations and Real-World Availability

While the FDA list is authoritative regarding *approval* and *reporting*, it has significant limitations when it comes to *current availability*. The FDA acknowledges that they do not always have information on whether an authorized generic is still being marketed or if marketing has ceased. This creates a gap between what is legally listed and what is actually on the shelf.

Industry feedback highlights this issue. A 2023 survey by the National Community Pharmacists Association found that 68% of independent pharmacists found the list difficult to use for practical purchasing decisions due to the lack of real-time data. For instance, a pharmacy owner might find a product on the FDA list with a recent market entry date, only to discover it isn't available from their wholesaler. To mitigate this, industry best practices recommend cross-referencing the FDA list with the National Drug Code (NDC) Directory and commercial sales databases like IQVIA. These tools track actual deactivations and sales volumes, giving you a more accurate picture of what patients can actually buy today.

Why Companies Use Authorized Generics

Understanding the strategy behind authorized generics helps explain why they exist. When a patent expires or litigation ends, traditional generic manufacturers can enter the market. However, the first generic to file often gets a 180-day period of marketing exclusivity, during which others cannot enter. Brand companies use authorized generics to blunt this impact. By launching their own authorized generic immediately, they can compete with the first-filing generic while maintaining control over supply and pricing. According to a 2023 Health Affairs study, this strategy led to 854 authorized generic launches in the U.S. between 2010 and 2019. While some argue this keeps prices higher than true competition would allow, it also ensures a consistent supply source from the original manufacturer.

Future Changes to the List

The current PDF format is expected to change. The FDA’s Center for Drug Evaluation and Research (CDER) has announced plans to transition to a dynamic, searchable database format by Q2 2026. This initiative responds to stakeholder requests for better search functionality and real-time updates. Until then, the PDF remains the single source of truth for official listings. Keep an eye on the FDA’s CDER strategic plan pages for updates on this transition, as it will significantly improve usability for researchers and healthcare providers.

Frequently Asked Questions